Zacks Small Cap Reduces Earnings Estimates for Edesa Biotech

Edesa Biotech, Inc. (NASDAQ:EDSA) – Zacks Small Cap dropped their FY2025 earnings estimates for shares of Edesa Biotech in a report released on Monday, May 19th. Zacks Small Cap analyst D. Bautz now anticipates that the company will post earnings of ($1.17) per share for the year, down from their previous estimate of ($1.02). The consensus estimate for Edesa Biotech’s current full-year earnings is ($1.75) per share.

Separately, HC Wainwright reissued a “buy” rating and set a $21.00 price objective on shares of Edesa Biotech in a research note on Thursday, March 13th.

Edesa Biotech Stock Performance

EDSA stock opened at $2.01 on Thursday. The stock has a market capitalization of $14.12 million, a P/E ratio of -1.07 and a beta of 0.55. Edesa Biotech has a one year low of $1.55 and a one year high of $5.59. The company has a 50 day moving average price of $2.28 and a two-hundred day moving average price of $2.15.

Edesa Biotech (NASDAQ:EDSA) last released its earnings results on Wednesday, May 14th. The company reported ($0.30) EPS for the quarter, hitting the consensus estimate of ($0.30).

Institutional Trading of Edesa Biotech

Institutional investors have recently made changes to their positions in the stock. Two Sigma Securities LLC purchased a new stake in shares of Edesa Biotech during the 4th quarter valued at $26,000. Nantahala Capital Management LLC purchased a new stake in shares of Edesa Biotech during the 1st quarter valued at $1,525,000. Velan Capital Investment Management LP purchased a new stake in shares of Edesa Biotech during the 1st quarter valued at $1,678,000. Stonepine Capital Management LLC purchased a new stake in shares of Edesa Biotech during the 1st quarter valued at $1,678,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Edesa Biotech during the 4th quarter valued at $70,000. 5.50% of the stock is owned by hedge funds and other institutional investors.

About Edesa Biotech

Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.